Neurotech International Enters Development Agreement for Cannabinoid Therapies

LOS ANGELES-  Neurotech International Limited, a clinical-stage biopharmaceutical company specializing in pediatric neurological disorders, has signed a development agreement with RH Pharma, a subsidiary of the European Cannabis Company (ECC). This collaboration aims to develop a pharmaceutical-grade, broad-spectrum cannabinoid drug product tailored for pediatric patients with neurodevelopmental disorders.

Under the agreement, RH Pharma will utilize its proprietary CO₂ extraction technology to produce a strain-agnostic cannabinoid formulation that aligns with Neurotech’s compositional standards and meets global regulatory requirements. This partnership is expected to enhance Neurotech’s production capabilities, ensuring scalability and consistency in anticipation of future product demand upon regulatory approvals.

Dr. Anthony Filippis, CEO and Managing Director of Neurotech International, emphasized the importance of this collaboration, stating that it accelerates the company’s global growth strategy and reinforces its commitment to delivering premium-quality products. Rebeka Levy, General Manager of ECC, expressed enthusiasm for the partnership, highlighting a shared vision for innovation and international expansion to meet the growing global demand for cannabinoid-based therapies.

This development aligns with Neurotech’s ongoing efforts to advance NTI164, its lead oral cannabinoid drug candidate, which has demonstrated significant improvements in clinical trials for conditions such as Autism Spectrum Disorder (ASD), Rett Syndrome, and PANDAS/PANS. The agreement with RH Pharma is poised to bolster Neurotech’s position in the biopharmaceutical industry, particularly in the realm of cannabinoid-based treatments for pediatric neurological conditions.